Critical Pharmaceuticals and the University of Nottingham have announced a new partnership for development of a "nano-enabled" intranasal formulation of teriparatide for the treatment of osteoporosis. Funding for the £545,000 collaboration is coming from the Technology Strategy Board and the Engineering and Physical Sciences Research Council (EPSRC). “We are … [Read more...] about Critical Pharmaceuticals and U. of Nottingham team on osteoporosis nasal spray
News
Acorda acquires Neuronex, diazepam nasal spray program
US pharmaceutical company Acorda Therapeutics President and CEO Ron Cohen has announced that the company is "excited" about an agreement with Neuronex, Inc. that will allow Acorda to acquire the company and its diazepam nasal spray program. Acorda has made an upfront payment of $2 million to acquire Neuronex, a North Carolina-based pharmaceutical company, plus … [Read more...] about Acorda acquires Neuronex, diazepam nasal spray program
Aptar introduces electronic dose counter and lockout for nasal sprays
Aptar Pharma is introducing two new eDevices, an electronic dose counter and an electronic lockout mechanism for nasal and sub-lingual spray pumps. The new devices can help products meet regulatory requirements for the delivery of controlled substances and are meant to help improve patient compliance. According to the company, the e-Dose Counter features a large, … [Read more...] about Aptar introduces electronic dose counter and lockout for nasal sprays
E-cigarette explodes in user’s mouth
According to news reports, a Florida man lost his teeth and part of his tongue when the battery in an e-cigarette exploded in his mouth on February 14. The explosion also started a fire in the man's home. Officials said that they were unable to determine the manufacturer of the e-cigarette. In October 2010, the US Court of Appeals ruled that the FDA has no … [Read more...] about E-cigarette explodes in user’s mouth
Mylan says it will challenge verdict in Sunovion Xopenex patent infringement suit
A jury has awarded $18 million to Sunovion Pharmaceuticals after finding that Mylan willfully infringed on patents for Xopenex levalbuterol hydrochloride inhalation solution when its subsidiary Dey marketed generic versions of the product. The trial took place in the US District Court for the District of Delaware. The patents involved are US patents numbers … [Read more...] about Mylan says it will challenge verdict in Sunovion Xopenex patent infringement suit
Herbal nasal sprays recalled
A Dallas, TX company called Wholistic Herbs Inc. has recalled all of the nasal spray products it distributed from March 2009 through February 2012 under the name "Koff & Kold" and "Kold Sore" after an FDA inspection determined that the products are not sterile. The products were distributed through the company's website, which is no longer accessible, and through … [Read more...] about Herbal nasal sprays recalled
EMA outlines objections to Adasuve MAA in Day 80 assessment report
Alexza Pharmaceuticals says that the Day 80 Assessment Report it has received from the European Medicines Agency (EMA) regarding its Marketing Authorization Application (MAA) for Adasuve Staccato loxapine indicates that the report "outlines major objections pertaining to the extrapolation of the Phase 3 study population to the intended patient population, pulmonary … [Read more...] about EMA outlines objections to Adasuve MAA in Day 80 assessment report
Generic Symbicort fails to show equivalence
Finnish pharmaceutical company Orion Corporation has announced its intention to continue development of a generic budesonide/formoterol DPI despite the fact that "equivalence with the reference product, which is required under the guideline of the European Medicines Agency, was not reached" in recent studies. According to the company, study results received early this … [Read more...] about Generic Symbicort fails to show equivalence
Insmed moving ahead with Arikace trials despite FDA clinical hold
Insmed Incorporated has announced that it will go ahead with two clinical trials of its Arikace liposomal amikacin for inhalation for non-tuberculous mycobacteria (NTM) lung disease and for P. aeruginosa infections in CF patients despite the continuing clinical hold placed by the FDA on the latter application. The FDA lifted the hold on Arikace for NTM earlier … [Read more...] about Insmed moving ahead with Arikace trials despite FDA clinical hold
Report estimates 6.2% increase in nebulizer sales over 5-year period
A new report from IbisWorld foresees a positive outlook for nebulizer sales after estimated annualized growth rate of 6.2% from 2007 to 2012. The report suggests that an aging population and increasing diagnoses of respiratory illnesses, plus an improving economy will help manufacturers to overcome "some market saturation and new federal regulations." Total revenue … [Read more...] about Report estimates 6.2% increase in nebulizer sales over 5-year period